Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

NCT03356054 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

COMBINATION_PRODUCT: R-DHAP
DRUG: Brentuximab Vedotin

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland